Bristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors. According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and […]
PsiOxus Therapeutics
PsiOxus Therapeutics shuffles the deck
PsiOxus Therapeutics shuffles the deck PsiOxus said it named Dr. Charles Morris as its chief development officer and Karen LaRochelle as its chief business officer. Morris comes from ImmunoGen, where he was chief development officer, bringing its lead candidate to Phase III development. Most recently, LaRochelle was the executive director of global business development at […]
